

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Biolex Therapeutics, Inc.		10/01/2010	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	MidCap Financial SBIC, LP		
Street Address:	7735 Old Georgetown Road		
Internal Address:	Suite 400		
City:	Bethesda		
State/Country:	MARYLAND		
Postal Code:	20814		
Entity Type:	LIMITED PARTNERSHIP: DELAWARE		
PROPERTY NUMBERS Total: 6			
Property Type	Number	Word Mark	
Registration Number:	3214518	EXPANDING PROTEIN POSSIBILITIES	
Registration Number:	3327291	LOCTERON	
Serial Number:	76643452	BIOLEX	
Serial Number:	76978827	BIOLEX	
Serial Number:	76978826	BIOLEX	
Serial Number:	76650345	BIOLEX	
CORRESPONDENCE DATA			
Fax Number:	(703)519-1821		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	703-415-1555		
Email:	mail@specializedpatent.com		
Correspondent Name:	Christopher E. Kondracki		
Address Line 1:	1725 Duke Street		
Address Line 2:	Suite 625		
Address Line 4:	Alexandria, VIRGINIA 22314		

CH \$165.00 3214518

ATTORNEY DOCKET NUMBER:	1010801-TM2
NAME OF SUBMITTER:	Christopher E. Kondracki
Signature:	/Christopher E. Kondracki/
Date:	11/09/2010

Total Attachments: 25
source=Biolex#page1.tif
source=Biolex#page2.tif
source=Biolex#page3.tif
source=Biolex#page4.tif
source=Biolex#page5.tif
source=Biolex#page6.tif
source=Biolex#page7.tif
source=Biolex#page8.tif
source=Biolex#page9.tif
source=Biolex#page10.tif
source=Biolex#page11.tif
source=Biolex#page12.tif
source=Biolex#page13.tif
source=Biolex#page14.tif
source=Biolex#page15.tif
source=Biolex#page16.tif
source=Biolex#page17.tif
source=Biolex#page18.tif
source=Biolex#page19.tif
source=Biolex#page20.tif
source=Biolex#page21.tif
source=Biolex#page22.tif
source=Biolex#page23.tif
source=Biolex#page24.tif
source=Biolex#page25.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

1st THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of the ___ day of October, 2010, by and between MIDCAP FINANCIAL SBIC, LP, a Delaware limited partnership (“Agent”), and BIOLEX THERAPEUTICS, INC., a Delaware corporation (“Grantor”).

RECITALS

A. The Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “Loans”) in the amounts and manner set forth in that certain Loan and Security Agreement by and between Agent, the Lenders, Grantor and Plantibodies Corporation dated as of the date hereof (as the same may be amended, modified or supplemented from time to time, the “Loan Agreement”; capitalized terms used but not defined herein are defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Intellectual Property to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property and Intellectual Property Proceeds (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following to the extent they are now or hereafter become Intellectual Property or Intellectual Property Proceeds of Grantor pursuant to the Loan Agreement:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral shall not include any of Grantor’s rights or interests in any license, contract or agreement to which Grantor is a party, or any of its rights or interests thereunder, to the extent (but solely to the extent) that a grant of a security interest would, under the terms of such license, contract or agreement or otherwise, result in a breach by Grantor of the terms of, or constitute a default by Grantor thereunder (other than to the extent that any such term would be rendered ineffective pursuant to the Code or any other applicable law or principles of equity); provided, however, that immediately upon the ineffectiveness, lapse or termination of any such provision, the Intellectual Property Collateral shall include, and Grantor shall be deemed to have granted a security interest in, all such rights and interests as if such provision had never been in effect.

This security interest is granted in conjunction with the security interest granted to Agent, for the ratable benefit of the Lenders, under the Loan Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.

Upon the occurrence of an IP Lien Release Event (as defined in the Loan Agreement), Agent's Lien in the Intellectual Property Collateral shall be released as more fully described in the Loan Agreement; *provided, however*, that Agent shall retain its Lien and all rights in and to all Intellectual Property Proceeds (as defined in the Loan Agreement), and accordingly, to the extent (but solely to the extent) necessary to permit attachment and perfection of Agent's security interest (on behalf of itself and Lenders) in such Intellectual Property Proceeds, the Intellectual Property Collateral shall include the related Intellectual Property, it being the understanding and intention of the parties that, after the occurrence of an IP Lien Release Event, Agent and Lenders shall not exercise any rights to sell, transfer, foreclose upon or otherwise dispose of or take ownership of the underlying Intellectual Property Collateral from which the Intellectual Property Proceeds were so derived.

[SIGNATURES APPEAR ON FOLLOWING PAGE(S)]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

158 Credle Street
Pittsboro, NC 27312
Attn: Finance Department

BIOLEX THERAPEUTICS, INC.,
a Delaware corporation

By: 
Name: DALE A. SANDER
Title: CHIEF FINANCIAL OFFICER

AGENT:

Address of Agent:

7735 Old Georgetown Road, Suite 400
Bethesda, Maryland 20814
Attn: Portfolio Management- Life Sciences

MIDCAP FINANCIAL SBIC, LP,
a Delaware limited partnership


By: 
Name: Josh Groman
Title: Managing Director

EXHIBIT A

Copyrights

Description

Registration/
Application
Number

Registration/
Application
Date

None*

*Grantor has not listed any over-the-counter software that is commercially available to the public.

EXHIBIT B**Patents**

<i>Assigned to Biolex</i>		
<i>Title</i>	<i>Serial No. / Filing Date</i>	<i>Status</i>
EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN DUCKWEED 1 Inventors: Stomp, Dickey, and Gasdaska	U.S. Utility Application SN 09/915,873 Filed 7/26/2001	U.S. Patent No. 6,815,184 Issued 11/9/2004 Expires 11/26/2021 (<i>Expression of Biologically Active Interferon in Duckweed</i>)
	U.S. C-I-P Appln. SN 10/675,011 Filed 9/30/2003	Published 8/31/2006 US2006/0195946 A1 Pending
	PCT Application SN PCT/US04/011968 Filed 4/16/2004	Published 4/21/2005 WO 2005/035768 Inactive [entered national phase (NP)]
	Australian NP Appln. SN 200480228	Pending
	Canadian NP Appln. SN 2,540,559	Pending
	Mexican NP Appln. SN PA/A/2006/003593	Pending
	PCT Application (<i>Alpha Interferon Variants</i>) SN PCT/US04/11965 Filed 4/16/2004	Published 4/21/2005 WO 2005/035767 Inactive [entered national phase (NP)]
	US NP Appln. (<i>Alpha Interferon Variants</i>) SN 10/574,046	Published 6/7/2007 US2007/0128162 Pending
	Australian NP Appln. (<i>Alpha Interferon Variants</i>) SN 2004280227	Pending
	Canadian NP Appln. (<i>Alpha Interferon Variants</i>) SN 2,540,884	Pending
Mexican NP Appln. (<i>Alpha Interferon Variants</i>) SN PA/A/2006/003589	Pending	

Assigned to Biolex

Title	Serial No. / Filing Date	Status
	U.S. C-I-P Application SN 10/794,615 Filed 3/5/2004	U.S. Patent No. 7,632,983 Issued 12/15/2009 Expires 11/26/2021
	U.S. Cont. Appln SN 11/778,480 Filed 7/16/2007	Pending
	PCT Application SN PCT/US01/23400 Filed 7/26/2001	Published 2/7/2002 WO 2002/010414 Inactive [entered national phase (NP)]
	Australian NP Application SN 2001288226	Australian Patent No. 2001288226 Issued 12/13/2007
	Australian Divisional Application SN 2007231691	Pending
	Canadian NP Application SN 2,417,415	Pending
	European NP Application SN 01967946.3	Allowed
	Chinese Divisional Application SN 200610059681.4	Pending
	Chinese Divisional Application SN 200910174763.7	Pending
	Indian NP Application SN 107/KOLNP/2003	Indian Patent No. 210345 Issued 10/03/2007
	Indian Divisional Appln. SN 1283/KOL/2006	Pending
	Indian Divisional Appln. SN 474/KOL/2010	Pending
	Japanese NP Application SN 2002-516330	Pending
	New Zealand NP Appln. SN 523912	NZ Patent No. 523912 Issued 07/07/2005
	Hong Kong NP Appln. SN 03107543.4	Pending
USE OF DUCKWEED IN HIGH THROUGHPUT SCREENING Inventors: Stomp, Dickey, Houghteling, and Rajbhandari	U.S. Utility Application SN 10/158,243 Filed 5/30/2002	U.S. Patent 7,709,699 Issued 05/04/2010 Expires 5/30/2022
	PCT Application SN PCT/US02/16938 Filed 5/30/2002	Published 12/5/2002 WO 02/097433 Inactive [entered national phase (NP)]

Assigned to Biolex

Title	Serial No. / Filing Date	Status
	Australian NP Application SN 2002257341	Australian Patent No. 2002257341 Issued 05/15/2008
	European NP Application SN 02726945.5	European Patent No. 1397676 Issued 12/30/2009
	Chinese NP Application SN 02812606.8	Chinese Patent No. ZL02812606.8 Issued 07/02/2008
	Indian NP Application SN 1527/KOLNP/2003	Indian Patent No. 237890 Issued 01/12/2010
	Japanese Application SN 2003-500561	Japanese Patent No. 4241370 Issued 01/09/2009
	New Zealand NP Appln. SN 529762	NZ Patent No. 529762 Issued 06/08/2006
	Singapore NP Application SN 200306897-0	Singapore Patent No. 100533 Issued 02/28/2006
	Russian NP Application SN 2003137841	Russian Patent No. 2298182 Issued 4/27/2007
<p>PLATE AND METHOD FOR HIGH THROUGHPUT SCREENING</p> <p>Inventor: Everett</p>	U.S. Utility Application SN 10/157,562 Filed 5/29/2002	U.S. Patent No. 7,326,385 Issued 02/05/2008 Expires 5/29/2022
	PCT Application SN PCT/US02/16645 Filed 5/29/2002	Published 12/5/2002 WO 02/097029 Inactive [entered national phase (NP)]
	Australian NP Application SN 2002303881	Australian Patent No. 2002303881 Issued 04/24/2008
	European NP Application SN 02731943.3	EP1427528 B1 Granted 5/24/2006 Grant Registered in: AT,BE,CH,DE,DK,ES,FI,FR,GB,DZ,HU, GR,IE,IT,LU,NL,PT,SE,TR,SK
	Chinese NP Application SN 02812117.1	Chinese Patent No. ZL02812117.1 Issued 09/17/2008
	Indian NP Application SN 1526/KOLNP/2003	India Patent No. 219931 Issued 05/14/2008
	Japanese NP Application SN 2003-500198	Japanese Patent No. 4471648 Issued 03/12/2010
	New Zealand NP Appln. SN 529761	New Zealand Patent No. 529761 Issued 2/8/2007
	Singapore NP Application SN 200306896-02	Singapore Patent No. 100532 Issued 02/28/2006
	Mexican NP Application SN PA/A/2003/010831	MX Patent No. 242000 Issued 11/15/2006
	Russian NP Application SN 2003137840	Russian Patent No. 2296619 Issued 4/10/2007
	Hong Kong NP Appln. SN 04105034.3	Hong Kong Patent No. 1062027 Issued 8/25/2006

Assigned to Biolex

Title	Serial No. / Filing Date	Status
LED ARRAY FOR ILLUMINATING CELL WELL PLATES AND AUTOMATED RACK SYSTEM FOR HANDLING THE SAME Inventor: Everett	U.S. Utility Application SN 10/080,918 Filed 2/22/2002	U.S. Patent No. 6,680,200 Issued 1/20/2004 Expires 2/22/2022
	PCT Application SN PCT/US03/04780 Filed 2/18/2003	Published 9/4/2003 WO 03/072685 Inactive [entered national phase (NP)]
	Australian NP Application SN 2003215281	Australian Patent No. 2003215281 Issued 10/02/2008
	Chinese NP Application SN 03804414.5	Chinese Patent No. ZL03804414.5 Issued 5/2/2007
	Japanese NP Application SN 2003-571375	Pending
	New Zealand NP Appln. SN 534917	NZ Patent No. 534917 Issued 7/12/2007
	Israeli NP Application SN 163569	Israeli Patent No. 163569 Issued 05/12/2009
	Singapore NP Application SN 200405465-6	Singapore Patent No. 109641 Issued 09/29/2006
	Mexican NP Application SN PA/A/2004/008174	Mexican Patent No. 252326 Issued 12/7/2007
	Russian NP Application SN 2004128242	Russian Patent No. 2315093 01/20/2008
	Hong Kong NP Appln. 05108102.3	Hong Kong Patent No. HK1076125 11/23/2007
BIOREACTOR FOR GROWING BIOLOGICAL MATERIALS SUPPORTED ON A LIQUID SURFACE Inventors: Vickers <i>et al.</i>	U.S. Utility Application SN 10/845,914 Filed 5/14/2004	U.S. Patent No. 7,176,024 Issued 2/13/2007 Expires 10/14/2024
	U.S. Continuation Appln. SN 11/469,675 Filed 09/01/2006	Published 5/23/2007 US 2007/0094926 A1 Pending
	U.S. C-I-P Appln. SN 11/469,663 Filed 09/01/2006	Published 5/24/2007 US 2007/0113474 A1 Pending
	PCT Application SN PCT/US07/077414 Filed 8/31/2007	Published 3/06/2008 WO 2008/028143 Pending
	PCT Application SN PCT/US04/16437 Filed 5/25/2004	Published 12/16/2004 WO 2004/108881 Inactive [entered national phase (NP)]
	Australian NP Application SN 2004245933	Pending
	Canadian NP Application SN 2,527,590	Pending

Assigned to Biolex

Title	Serial No. / Filing Date	Status
	European NP Application SN 04753293.2	Pending
	European Div. Appln. SN 08004456.3	Pending
	Chinese NP Application SN 200480018305.X	Chinese Patent No. ZL200480018305.X Issued 11/05/2008
	Chinese Div. Appln. SN 200810080756.6	Pending
	Indian NP Application SN 5448/DELNP/2005	Indian Patent No. 237056 Issued 12/02/2009
	Japanese NP Application SN 2006-514953	Pending
	New Zealand NP Appln. SN 544321	New Zealand Patent No. 544321 Issued 03/13/08
	Israeli NP Application SN 172181	Pending
	Singapore NP Application SN 200507591-6	Singapore Patent No. 117751 Issued 1/31/2008
	Singapore Div. Appln. SN 200718134-0	Pending
	Mexican NP Application SN PA/A/2005/012938	Mexican Patent No. 257641 Issued 06/03/2008
	Russian NP Application SN 2005141420	Allowed
	South Korean NP Appln. SN 10-2005-7022943	Pending
	Hong Kong NP Appln. SN 07101165.0	Hong Kong Patent No. HK 1096422 Issued 06/19/2009
	Hong Kong Div. Appln. SN 09102015.08	Pending Based on Chinese Div. Appln. SN 200810080756.6
ASEPTIC BIOREACTOR SYSTEM FOR PROCESSING BIOLOGICAL MATERIALS Inventors: Everett	U.S. Provisional Application SN 61/153,451 Filed 2/18/2009	Pending
	PCT Application SN PCT/US2010/024570 Filed 02/18/2010	Pending
EXPRESSION OF PLASMINOGEN AND MICROPLASMINOGEN IN DUCKWEED Inventors: Spencer <i>et al.</i>	U.S. Utility Application SN 11/056,621 Filed 2/11/2005	U.S. Patent No. 7,659,445 Issued 02/09/2010 Expires 2/11/2025
	PCT Application SN PCT/US2005/004245 Filed 2/11/2005	Published 8/25/2005 WO 2005/078109 Inactive [entered national phase (NP)]

Assigned to Biolex

Title	Serial No. / Filing Date	Status
	Australian NP Application SN 2005212431	Allowed
	Brazilian NP Application SN PI0507613-7	Pending
	Canadian NP Application SN 2,555,609	Pending
	Chinese NP Application SN 200580010145.9	Pending
	European NP Application SN 05722918.9	Pending
	Hong Kong Application SN 06112490.4	Published 12/29/2006 Publication No. 1090667 Pending
	Indian NP Application SN 5061/DELNP/2006	Pending
	Israeli NP Application SN 177435	Pending
	Japanese NP Application 2006-553230	Published 1/9/2007 Publication No. 10-2007-0004706 Pending
	Korean NP Application SN 10-2006-7018571	Published 1/9/2007 Publication No. 10-2007-0004706 Pending
	Mexican NP Application PA/A/2006/009240	Pending
	Russian Federation Appln. SN 2006132394	Allowed
	New Zealand NP Appln. SN 549537	New Zealand Patent No. 549537 Issued 01/07/2010
	Singapore NP Application SN 200605488-6	Singapore Patent No. 124788 Issued 02/27/2009
COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS Inventors: Dickey <i>et al.</i>	U.S. Utility Application SN 11/624,164 Filed 1/17/2007	Published 3/13/2008 US 2008/0066200 A1 Pending (Biolex)
	PCT Application SN PCT/US07/060642 Filed 1/17/2007	Published 7/26/2007 WO 2007/084922 Inactive [entered national phase (NP)] (Biolex)
	Australian NP Application SN 2007205935	Pending
	Brazilian NP Application SN PI 0707289-9	Pending

Assigned to Biolex

Title	Serial No. / Filing Date	Status
	Canadian NP Application SN 2,637,252	Pending
	Chinese NP Application SN 200780009540.4	Pending
	European NP Application SN 07718188.1	Pending
	Hong Kong Application SN 08111335.3	Published 02/06/2009 Publication No. 1118309A Pending
	Indian NP Application SN 3348/KOLNP/2008	Pending
	Israeli NP Application SN 192761	Pending
	Japanese NP Application SN 2008-550560	Pending
	Korean NP Application SN 10-2008-7019978	Pending
	Mexican NP Application SN MX/a/2008/009221	Pending
	Russian Federation Appln. SN 2008133626	Pending
	New Zealand NP Appln. SN 570331	Pending
	Singapore NP Appln. SN 200805205-2	Pending
	U.S. Utility Application SN 11/624,158 Filed 1/17/2007	Published 3/6/2008 US 2008/0060092 A1 Pending (Biolex/Wang)
	PCT Application SN PCT/US07/060646 Filed 1/17/2007	Published 7/26/2007 WO 2007/084926 Inactive [entered national phase (NP)] (Biolex/Wang)
	Australian NP Application SN 2007205939	Pending
	Brazilian NP Application SN PI 0707290-2	Pending
	Canadian NP Application SN 2,637,254	Pending
	Chinese NP Application SN 200780009451.X	Pending
	European NP Application SN 07719154.3	Pending
	Hong Kong Application SN 08111105.1	Published 12/12/2008 Publication No. 1115888A Pending

Assigned to Biorex

Title	Serial No. / Filing Date	Status
	Indian NP Application SN 3342/KOLNP/2008	Pending
	Israeli NP Application SN 192802	Pending
	Japanese NP Application SN 2008-550562	Pending
	Korean NP Application SN 10-2008-7020032	Pending
	Mexican NP Application SN MX/a/2008/009220	Pending
	Russian Federation Appin. SN 2008133628	Pending
	New Zealand NP Appin. SN 570330	Pending
	Singapore NP Application SN 200805320-9	Pending
GLYCAN-OPTIMIZED ANTI-CD20 ANTIBODIES Inventor: Dickey <i>et al.</i>	U.S. Utility Application SN 12/115,133 Filed 05/05/2008	Pending
EXPRESSION CONTROL ELEMENTS FROM THE LEMNACEAE FAMILY Inventors: Dickey <i>et al.</i>	U.S. Utility Application SN 11/653,593 Filed 1/16/2007	U.S. Patent No. 7,622,573 Issued 11/24/2009 Expires 1/16/2027
	U.S. Div. Application SN 12/581,752 File 10/19/2010	Pending
	PCT Application PCT/US07/060614 Filed 1/17/2007	Published 11/1/2007 WO 2007/124186 Inactive [entered national phase (NP)]
	Australian NP Application SN 2007240573	Pending
	Brazilian NP Application SN PI 0707291-0	Pending
	Canadian NP Application SN 2,637,222	Pending
	Chinese NP Application SN 200780007583.9	Pending
	European NP Application SN 07797081.2	Pending
	Hong Kong Application SN 08111221.0	Pending
	Indian NP Application SN 3236/KOLNP/2008	Pending

Assigned to Biorex		
Title	Serial No. / Filing Date	Status
	Israeli NP Application SN 192760	Pending
	Japanese NP Application SN 2008-550559	Pending
	Korean NP Application SN 10-2008-7019975	Pending
	Mexican NP Application SN MX/a/2008/009219	Pending
	Russian Federation Appl. SN 2008133627	Pending
	New Zealand NP Appln. SN 570329	Pending
	Singapore NP Application SN 200805203-7	Pending
HUMANIZED ANTI-CD20 ANTIBODIES AND METHODS OF USE	U.S. Non-Provisional Application No. 12/720,483 Filed 03/9/2010	Pending
	PCT Application No. PCT/US10700449	Pending
C-TERMINALLY TRUNCATED INTERFERON Inventors: Reinl and Pogue	U.S. Cont. Appln. SN 11/874,607 Filed 10/18/2007	Pending
	PCT Application SN PCT/US2005/026674 Filed 7/27/2005	Published 2/09/2006 WO 2006/015057 Inactive [entered national phase (NP)]
	Australian NP Appln. SN 2005/269364	Pending
	Canadian NP Appln. SN 2,579,214	Pending
	Hong Kong NP Appln. SN 07111901.8	Pending
COMPOSITIONS AND METHODS FOR PRODUCTION OF AGLYCOSYLATED PLASMINOGEN Inventors: Dickey <i>et al.</i>	U.S. Provisional Application SN 61/181,170 Filed 05/26/2009	Pending

Assigned to Biolex

<i>Title</i>	<i>Serial No. / Filing Date</i>	<i>Status</i>
METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF DUCKWEED Inventors: Parsons and Wingate	U.S. Provisional Application SN 61/219/578 Filed 06/23/2009	Pending
STABLE INTERFERON FORMULATIONS	U.S. Provisional Application No. SN 61/285,589 Filed 01/15/2010	Pending
CONTROLLED/SUSTAINED RELEASE INTERFERON DRUG PRODUCTS AND TREATMENT OF HCV INFECTION USING SAME Inventors: Spencer, Humphries, de Leede, and Verrijck	U.S. Non-Provisional Application SN 12/180,214 Filed 07/25/2008	Pending U.S. Publication No. 2009/0068280 A1
	PCT Application SN PCT/US08/71191 Filed 07/25/2008	Pending PCT Publication No. WO2009/015336
	Australian Application No. 2008279087 Filed 07/25/2008	Pending
	Brazilian Application No. PI0814363-3	Pending
	Canadian Application No. 2694440	Pending
	Chinese Application No. 2008800109654.0	Pending
	European Application No. 08782397.7	Pending
	Indian Application No. 1082/DELNP/2010	Pending
	Israeli Application No. 203439	Pending
	Japanese Application No. 2010-518412	Pending
	Mexican Application No. MX/a/2010/000965	Pending
	Russian Application No. 2010106646	Pending
	South African Application No. 2010/00681	Pending
South Korean Application No. 10-2010-7004036	Pending	
CONTROLLED RELEASE COMPOSITIONS FOR INTERFERON BASED ON	U.S. Non-Provisional Application SN 11/774,107 Filed 01/06/2006	U.S. Patent No. 7,736,674 Issued 06/15/2010 Expires 1/6/2026

Assigned to Biolex

Title	Serial No. / Filing Date	Status
<p>PEGT/PBT BLOCK COPLOYMERS</p> <p>(New Continuation/Divisional applications will be filed with claims directed to manufacturing methods; a one-half undivided interest in these new applications will be assigned to OctoPlus)</p>	<p>U.S. Non-Provisional Application SN 12/466,430 Filed 05/15/2009</p>	<p>Pending U.S. Publication 2009/0226532 A1</p>
	<p>U.S. Continuation Application No. 12/625,929 Filed 11/25/2009</p>	<p>Pending</p>
	<p>European Application SN 06700417 Filed 01/06/2006</p>	<p>European Patent No. 1843749 B1</p> <p>Registered:</p> <ul style="list-style-type: none"> Albania 1843749 Austria E431134 Bosnia and Herzegovina 1843749 Belgium 1843749 Bulgaria 1843749 Switzerland 1843749 Cyprus 1843749 Czech Republic 1843749 Germany 602006006797.6 Denmark 1843749 Estonia 1843749 Spain 1843749 Finland 1843749 France 1843749 United Kingdom 1843749 Greece 1843749 Croatia 1843749 Hungary 1843749 Ireland 1843749 Iceland 1843749 Italy 1843749 Lithuania 1843749 Luxemburg 1843749 Latvia 1843749 Monaco 1843749 Macedonia 1843749 Netherlands 1843749 Poland 1843749 Portugal 1843749 Romania 1843749 Serbia 1843749 Sweden 1843749 Slovenia 1843749 Slovakia 1843749 Turkey 1843749
	<p>PCT Application SN PCT/NLO06/000006 Filed 01/06/2006</p>	<p>Pending PCT Publication No. W02006/085747 A1</p>

Assigned to Biorex

Title	Serial No. / Filing Date	Status
	European Application SN 07120539.7 Filed 01/06/2006	Pending European Publication No. 1886668 A1
	Australian Application SN 2006213168 A1 Filed 01/06/2006	Pending Australian Publication No. 2006213168 A1
	Brazilian Application SN PI0606514-7 Filed 01/06/2006	Pending
	Canadian Application SN 2594434 Filed 01/06/2006	Pending Canadian Publication No. 2,594,434 A1
	Chinese Application SN 200680007430.X Filed 01/06/2006	Pending Chinese Publication No. 1011373-49A
	Indian Application SN 3461/CHENP/2007 Filed 01/06/2006	Pending
	Mexican Application SN MX/a/2007/008293 Filed 01/06/2006	Pending
	Singapore Application SN 2007-05063-6 Filed 01/06/2006	Pending
	Japanese Application SN 2007-550316 Filed 01/06/2006	Pending
	Russian Application SN 2007130090 Filed 01/06/2006	Pending
	Korean Application SN 10-2007-7018068 Filed 01/06/2006	Pending Korean Publication No. 10-2007-0118225
	Israeli Application SN 184431 Filed 01/06/2006	Pending
	Singapore Application No. 201000063-6 Filed 01/06/2006	Pending
	Chinese Application No. 200910207704.5	Pending
Co-Owned by Biorex With OctoPlus		
POLYETHERESTERS COPOLYMERS AS DRUG	U.S. Application SN 08/699,896 Filed 08/16/1996	U.S. Patent No. 5,980,948 Issued 11/09/1999 Expires 8/16/2016

Assigned to Biolex

Title	Serial No. / Filing Date	Status
DELIVERY MATRICES	European Patent No. EP0830859 B1	Issued 12/10/2003 Registered in: Austria AT 255884 Belgium BE 0830859 Switzerland CH 0830859 Germany DE 69726672.9 Denmark DK 0830859 Spain ES 2212037 Finland FI 0830859 France FR 0830859 United Kingdom GB 0830859 Greece GR 0830859 Ireland IE 0830859 Italy IT 0830859 Luxembourg LU 0830859 Netherlands NL 0830859 Portugal PT 0830859 Sweden SE 0830859
	European Patent No. EP1247522 B1	Issued 05/19/2004 Registered in: Austria AT 267006 Belgium BE 1 247 522 Switzerland CH 1 247 522 Germany DE 69729228 Denmark DK 1 247 522 Spain ES 2 221 916 Finland FI 1 247 522 France FR 1 247 522 United Kingdom GB 1 247 522 Greece GR 1 247 522 Ireland IE 1 247 522 Italy IT 1 247 522 Luxembourg LU 1 247 522 Netherlands NL 1 247 522 Portugal PT 1 247 522 Sweden SE 1 247 522
	Canadian Application SN 2,213,368 Filed 08/18/1997	Canadian Patent No. 2,213,368 Issued 04/01/2008
	PCT Application SN PCT/US97/13932 Filed 08/07/1997	PCT Publication No. WO98/06439

Co-Owned by Biogen with Medarex, Inc.		
MONOCLONAL ANTIBODIES AGAINST CD30 LACKING FUCOSYL AND XYLOSYL RESIDUES	PCT Application SN PCT/US07/01451 Filed 01/17/2007	Published 07/26/2007 WO 2007/084672 Inactive [entered national phase (NP)]
	U.S. NP Appln. SN 12/160,990	Pending
	European NP Appln. SN 2007718000	Pending
Inventors: Black <i>et al.</i>		

Exclusive License to Biolex from North Carolina State University pursuant to License Agreement dated April 30, 1998, by and between Biolex and North Carolina State University

Title	Serial No. / Filing Date	Status
GENETICALLY ENGINEERED DUCKWEED Inventors: Stomp and Rajbhandari	U.S. Utility Application SN 09/132,536 Filed 8/11/1998	U.S. Patent No. 6,040,498 Issued 3/21/2000 Expires 8/11/2018
	U.S. Continuation Appln. SN 10/677,441 Filed 10/2/2003	Published 4/15/2004 US2004/0073968 A1 Pending
	U.S. Continuation Appln. SN 10/273,974 Filed 10/18/2002	U.S. Patent No. 7,161,064 Issued 1/9/2007 Expires 8/11/2018
	U.S. Continuation Appln. SN 11/590,071 Filed 10/31/2006	Published 2/22/2007 US2007/0044177 A1 Pending
	2PCT Application 3SN PCT/US98/16683 Filed 8/11/1998	Published 2/18/1999 WO 99/007210 Inactive [entered national phase (NP)]
	European NP Application 4SN EP19980939350	Published 9/27/2000 EP1037523 Pending
	Japanese NP Application 5SN 2000-506820	Published 9/04/2001 2001-513325 Pending
	Canadian NP Application 6SN 2,288,895	Pending
	7Australian NP Application SN 87799/98 Filed 08/11/1998	Australian Patent No. 755632 Issued 4/17/2003
	8Australian Divisional Appln. SN 2006/202219 9Filed 08/11/1998	Australian Patent No. 2006202219 Issued 4/24/2008
	10Australian Div. Appln. SN 2008201438	Pending
	Chinese Divisional Appln. SN 200610084123.3	Allowed
	Chinese Divisional Appln. SN 200910145410.4.4	Pending
Mexican NP Application SN PA/A/2000/001464 11	Pending	

Exclusive License to Biolex from North Carolina State University pursuant to License Agreement dated April 30, 1998, by and between Biolex and North Carolina State University

Title	Serial No. / Filing Date	Status
	Mexican Divisional Appln. SN PA/A/2006/004240	Pending
	Mexican Divisional Appln. SN PA/A/2006/004248	Pending
	Israeli NP Application 12 SN 132,580	Pending
	Israeli Div. Appln. SN 193,758	Pending
	Hong Kong NP Appln. 13 SN 01102104.8	Published 6/15/2001 1031297A Pending

Exclusive License to Biolex from OctoPlus pursuant to Product Rights Acquisition Agreement dated October 3, 2008, by and between Biolex and OctoPlus

METHODS FOR THE PREPARATION OF PURIFIED MICROPARTICLES (Currently in the process of establishing co-ownership of these patents)	U.S. Application SN 10/493,906 Filed 10/23/2002	U.S. Patent No. 7,468,151 Issued 12/23/2008 Expires 10/23/2022
	European Patent No. 1306127B1	Issued 12/26/2007 Registered in: Austria AT 381963 Belgium BE 1 306 127 Switzerland CH 1 306 127 Lichtenstein LI 1 306 127 Germany DE 60132094 France FR 1 306 127 United Kingdom GB 1 306 127 Ireland IE 1 306 127 Netherlands NL 1 306 127
	Canadian Application SN 2,464,668 Filed 10/23/2002	Pending
	PCT Application SN PCT/NL02/00672 Filed 10/23/2002	PCT Publication No. WO03/035244

Exclusive License to Plantibodies from The Scripps Research Institute pursuant to License Agreement between The Scripps Research Institute and EPiocyte Pharmaceutical, Inc. (October 9, 1997) as assigned to and assumed by Biolex by letter dated April 22, 2004

<i>Title</i>	<i>Serial No. / Filing Date</i>	<i>Status</i>
COMPOSITIONS CONTAINING PLANT PRODUCED GLYCOPOLYPEPTIDE MULTIMERS, MULTIMERIC PROTEINS, AND METHOD OF THEIR USE Inventors: Hiatt <i>et al.</i>	U.S. Continuation Appln. SN 07/971,951 Filed 11/5/1992	U.S. Patent No. 5,639,947 Issued 6/17/1997 Expires 6/17/2014
	PCT Application SN PCT/US90/06179 Filed 10/25/1990	Published 5/16/1991 WO 91/006320 Inactive [entered national phase (NP)]
	European Divisional Application SN 00200970.2	European Patent No. EP 1048734 B1 Granted 08/13/2008
	Japanese Divisional Appln. SN 2000-251610	Japanese Patent No. 3920545 Issued 3/06/2007
	Japanese Divisional Appln. SN 2004-293032 Filed 10/05/2004	Japanese Patent No. 4045268 Issued 12/04/2007

Exclusive License to LemnaGene from YEDA Research Corporation Ltd pursuant to Agreement for Resolution of Patent Controversies among North Carolina State University, LemnaGene S.A., Yeda Research Corporation Ltd. and Biolex (July 7, 2005) and License Agreement among LemnaGene, Yeda and Biolex (July 7, 2005).

Title	Serial No. / Filing Date	Status
TRANSGENIC LEMNACEAE Inventors: Edelman <i>et al.</i>	U.S. Utility Application SN 09/529,172 Filed 10/8/1998	U.S. Patent No. 7,176,352 Issued 2/13/2007 Expires 10/10/2017
	PCT Application SN PCT/IL98/00487 Filed 10/8/1998	Published 4/22/1999 WO 99/019497 Inactive [entered national phase (NP)]
	European NP Application SN 98947760.9	European Patent No. 1021552 B1 1/09/2008
	Canadian NP Application SN 2,312,008	Pending
	Israeli NP Application SN 135543	Pending
	Australian NP Application SN 94572/98	Australian Patent No. 759570 Issued 4/17/2003
	Australian Divisional Appln. SN200300734	Australian Patent No. 20300734 Issued 04/05/2007

Non-exclusive License to Biolex from Phytomedics (with Option for Exclusivity), pursuant to License Agreement dated 02/25/2010 by and between Biolex and Phytomedics, Inc.

Title	Serial No. / Filing Date	Status
METHODS OF RECOVERING POLYPEPTIDES FROM PLANTS AND PORTIONS THEREOF Inventor: Raskin	U.S. Utility Application SN 09/015,605 Filed 01/30/1998	U.S. Patent No. 6,096,546 Issued 08/01/2000 Expires 1/30/2018
	PCT Application SN PCT/US99/02071 Filed 01/29/1999	Published 08/05/1999 WO 99/38990 Inactive [entered national phase (NP)]
	Australian NP Appln. SN 0025701/99	Australian Patent No. 768697 Issued 04/29/2004
	European NP Appln. SN 99905568.4	European Patent No. 1049792 B1 Granted 10/10/2007
	Canadian NP Appln. SN 0002319732	Pending
	Japanese NP Appln. SN 2000529448	Allowed 06/01/2009

EXHIBIT C

Trademarks

<i>Trademarks Held by Biolex.</i>		
<i>Mark</i>	<i>Serial No. / Filing Date</i>	<i>Status</i>
Biolex	U.S. Application SN 76/643,452 Filed 7/22/2005 Classes 1 and 5	U.S. Notice of Allowance
Biolex	U.S. Application SN 76/978,827 Classes 40 and 42	Registration No. 3,510,483 Registered 10/07/2008
Biolex (Stylized)	U.S. Application SN 76/650,345 11/12/2005 Classes 1 and 5	U.S. Notice of Allowance
Biolex (Stylized)	U.S. Application SN 76/978,826 Classes 40 and 42	Registration No. 3,510,483 Registered 10/07/2008
Expanding Protein Possibilities®	U.S. Application SN 76/644,386 Filed 8/9/2005	Registration No. 3,214,518 Registered 3/6/2007
Locteron®	U.S. Application SN 78/810,649 Filed 2/9/2006	Registration No. 3,327,291 Registered 10/30/2007
Biolex Therapeutics™	N/A	In use but has not been registered for trademark protection.

EXHIBIT D

Mask Works

Description

Registration/
Application
Number

Registration/
Application
Date

None